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ABSTRACT  
 
Recombinant proteins have revolutionized the biomedical industry, providing 
therapeutics for life-threatening diseases and protein reagents for research applications. 
BioMarin Pharmaceutical Inc. develops recombinant protein therapeutics to treat rare 
diseases including lysosomal storage disorders (LSDs), a group of about 50 individually 
rare disorders together affecting 1 in 8,000 live births. With an increase in the number of 
novel therapeutics in our drug discovery pipeline, there is a high demand to produce a 
variety of recombinant proteins for early-stage drug development projects. In order to 
equip our protein production process with the tools and capability for diverse protein 
expression, it is valuable to expand our expression toolbox with high-expressing 
platforms. The goal of this project is to expand to our current expression platforms by 
developing a murine myeloma based expression system with SP2/0 cells as a host. Since 
the SP2/0 cell line is amongst the most commonly used cell lines for therapeutic and 
reagent protein production, developing a SP2/0 expression system may offer additional 
benefits to our recombinant protein production needs including: expression of difficult-
to-express proteins, improving titers, and extending recombinant cell line stability. A 
lysosomal enzyme therapeutic candidate is expressed in the SP2/0 cells as a proof-of-
concept for developing this protein expression platform.  To this end, we have shown that 
SP2/0 cells can be grown to a high density in commercially available serum-free media 
with a doubling time of less than twenty four hours. A clone isolation strategy was used 
to pick the top clone expressing high levels of recombinant protein. Using the highest 
expressing clone, we developed a high yielding bioprocess at a two liter scale to 
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demonstrate the utility of this system for generating recombinant proteins at large scale. 
Furthermore, the therapeutic properties of the recombinant protein expressed in SP2/0 
cells are similar to the recombinant protein expressed in CHO cell lines, demonstrating 
similar uptake into diseased cells (Kuptake values) and binding affinity to the receptor 
responsible for drug mediated cellular uptake.  Thus, the SP2/0 expression system proves 
to be a valuable addition to our expression toolbox for the production of research-grade 
protein therapeutics for cell-based assays. 
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1.0 INTRODUCTION  
 
Development of recombinant proteins for therapeutic and research purposes 
represent one of the fastest expanding branches of the biotech industry. BioMarin 
Pharmaceutical Inc. utilizes recombinant protein technology to develop protein 
treatments for patients with rare genetic disorders including lysosomal storage diseases 
(LSDs). Although each LSD is individually rare, the entire group of LSDs affect 1 in 
8,000 live births and make up a significant fraction of diseases caused by inborn errors of 
metabolism (Platt, Boland, & van der Spoel, 2012; M. Xu et al., 2016). LSDs are 
characterized by disruption of lysosomal homeostasis, due to the deficiency of a 
lysosomal enzyme, lysosomal membrane protein, or other proteins necessary for 
lysosomal biogenesis. Since the lysosome is essential for degrading and recycling 
macromolecules from autophagy, endocytosis, and phagocytosis, cell metabolism is 
significantly impacted when the lysosome malfunctions (Appelqvist, Wäster, Kågedal, & 
Öllinger, 2013). For example, lysosomal disruption eliminates downstream recycled 
products necessary for cellular functions, causing cellular problems including 
mitochondrial dysfunction, inflammation, altered calcium homeostasis, and accumulation 
of toxic waste products (Appelqvist et al., 2013). Patients with LSDs display a range of 
clinical symptoms depending on the type of LSD. Generally, clinical phenotypes of LSDs 
include damage to the central nervous system, bone abnormalities, and organomegaly 
(Meikle, Hopwood, Clague, & Carey, 1999). The severity of the symptoms from LSDs 
vary depending on the type of accumulating substrate, the amount of functioning 
hydrolase activity, and the tissue affected by the accumulating substrate.  
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Currently, there are limited options to improve or restore the enzymatic activity of 
the missing lysosomal hydrolase in patients with LSDs. Current therapeutic approaches 
include hematopoietic stem cell transplantation, enzyme replacement therapy, gene 
therapy, substrate reduction therapy, and chaperone therapy (Bruni, LoSchi, coppa, & 
Bruni, 2007). Enzyme replacement therapy (ERT) is currently the most widely-used 
therapy to treat LSDs especially in the cases where lysosomal enzyme production is 
affected (Parenti, Pignata, Pietro, & Salerno, 2013). As the name suggests, ERT is the 
therapeutic approach to replace or restore deficient enzymatic activity by delivering the 
functional recombinant lysosomal enzymes into the cell and its lysosome. This critical 
step of delivering the drug to the lysosomal compartment is achieved by endocytosis of 
the recombinant protein through the binding with mannose-6-phosphate (M6P) receptors. 
In 1990, the first successful ERT used recombinant galactocerebrosidase to treat patients 
with Gaucher’s disease (Neufeld, 2006). As of 2013, commercially available ERT 
treatments are available for six LSDs (Ratko, Marbella, Godfrey, & Aronson, 2013).  
A key component to producing an effective ERT is to ensure that the recombinant 
enzyme contains M6P residues on N-glycans, glycans that are covalently bound to 
asparagine residues on a protein (Stanley, Schachter, & Taniguchi, 2009). The mannose-
6-phosphate residues serve as a recognition marker for the transport of newly-synthesized 
enzymes into the lysosome (Figure 1). In healthy cells, lysosomal enzymes are 
synthesized and glycosylated on the N-linked oligosaccharide residues in the 
endoplasmic reticulum. Then, lysosomal enzymes are modified with M6P residues during 
a two-step reaction process in the Golgi apparatus. During the first step, a 
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phosphotransferase, UDP-N-acetylglucosamine 1-phosphotransferase (GlcNAc-1-
phosphotransferase) catalyzes a reaction allowing the transfer of a GlcNAc-1-phosphate 
residue from UDP-GlcNAc to specific mannose sites on the N-linked oligosaccharides on 
the lysosomal enzymes (Coutinho, Prata, & Alves, 2012). The second step requires an 
uncovering enzyme, N-acetylglucosamine-1-phosphodiester α-N-acetyl-glucosaminidase 
(UCE), which removes the GlcNAc residue, uncovering the M6P residue (Coutinho et al., 
2012). At the trans-face of the Golgi, the lysosomal enzymes with the M6P recognition 
marker are separated from other newly-synthesized proteins by binding to M6P receptors. 
Next, the lysosomal enzymes bound to the M6P receptors are packaged in clathrin-coated 
vesicles and bud off from the Golgi apparatus. The clathrin-coated vesicles containing the 
lysosomal enzyme then fuse with late endosomes (Coutinho et al., 2012).  As the internal 
pH of the endosome lowers during lysosomal maturation, the lysosomal enzymes become 
active and can function to degrade macromolecules within the cell.  
 
 
  
4 
 
 
Figure 1. Transport of lysosomal enzymes to the lysosome 
 
Newly synthesized lysosomal proteins are transported to the lysosome by the mannose-6-
phosphate pathway.  
Source: Coutinho et al., 2012 
 
In addition to the transport of newly synthesized enzymes to the lysosome, M6P 
residues are also important for the internalization of extracellular lysosomal enzymes, for 
example ERTs (Figure 2). Two types of mannose-6-phosphate receptors, the cation-
independent M6P receptor (CI-M6PR) and the cation-dependent M6P receptor (CD-
M6PR) are scattered along the surface of the plasma membrane. Upon binding of an 
extracellular M6P-marked enzyme, to the CI-M6PR, the enzyme is endocytosed and can 
be transported to the lysosome. Although the CD-M6PR and the CI-M6PR both mediate 
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trafficking of newly-synthesized endogenous lysosomal enzymes to the lysosome, 
extracellular M6P-marked lysosomal enzymes are only internalized into the cell upon 
binding to the CI-M6PR (Saftig, 2006). Another key component of a successful ERT is to 
manufacture the lysosomal enzyme in its active conformation. ERTs need to be active to 
degrade accumulating macromolecules within diseased cells. Due to the critical role of 
M6P residues, all ERT production host candidates must have complex glycosylation 
capabilities.  
 
Figure 2. Cellular uptake of recombinant enzymes by M6P pathway 
 
Extracellular uptake of extracellular recombinant enzymes including ERTs, are mediated 
by the M6P. Binding of extracellular M6P-marked lysosomal enzymes to the M6P 
receptors on the plasma membrane of the cell initiates enzyme delivery to the lysosome 
by the endocytic route (dotted arrows).  
Source: Parenti et al., 2013 
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Most commonly, Escherichia coli (E. coli), mammalian cells, yeast, or 
baculovirus-infected insect cells are used as hosts to produce biologics. While producing 
biologics in bacteria is cheaper, faster to grow, and yield higher titers compared to 
mammalian cells, bacteria lack appropriate machinery to post-translationally modify 
proteins with glycoproteins, a critical component to biologic drug efficacy and uptake 
efficiency (Jayapal, Wlaschin, Hu, & Yap, 2007). Most biologics require human 
glycosylations, usually N-glycans, where the glycosylation site is on the asparagine 
residue (e.g. ERTs), and sometimes O-glycans, where the glycosylation site is on the 
serine or threonine residues (Ghaderi, Zhang, Hurtado-Ziola, & Varki, 2012; Solá & 
Griebenow, 2010). Variation in glycan branching pattern, length, and the arrangement of 
monosaccharides also add complexity to N-glycan structure (Solá & Griebenow, 2010). 
All N-glycans fall into one of the three categories: high-mannose, complex, or hybrid 
(Figure 3). The type of N-glycan structure added to a recombinant protein is dependent 
on the cellular machinery of the cell host. M6P residues are usually added to complex N-
glycans on human lysosomal enzymes. Furthermore, human proteins have additional 
structural variation since the terminal ends of the glycan contain variations of chemically-
charged glycans, such as sialic acid. These chemically-charged glycans are important for 
drug efficacy because they affect the isoelectric point (pI) and the surface charge of the 
protein therapeutic (Solá & Griebenow, 2010). Ideally, protein therapeutics should mimic 
human protein glycosylations to improve drug efficacy and minimize immunogenicity to 
the drug. Recently, new genetic modifications in yeast and insect cells have improved the 
cell’s capability of post-translationally modifying proteins. However, post-translational 
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modifications (PTMs) from yeast and insect cells are still limited to simple PTMs or do 
not have the complex human glycosylation patterns, impairing drug quality (Figure 4).  
 
Figure 3. Types of N-glycans 
 
The structures of the three major categories of N-glycans: high mannose, complex, and 
hybrid. All N-glycan types are added to proteins on the asparagine residues. All 
structures have two N-acetylglucosamine (GlcNAc) residues followed by three mannose 
residues.  
Source: Higel, Seidl, Sorgel, & Friess, 2016 
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Figure 4. Comparison of N-glycan structures from different expression platforms 
 
Above are examples of N-glycan structures added to biologics in different eukaryotic 
expression platforms during protein production. The first step of N-glycan synthesis 
occurs in the endoplasmic reticulum (ER), where glycosylation machinery in all species 
are highly conserved, generating the common Man3GlcNAc2 structure. Glycosylation in 
the Golgi apparatus varies greatly among different species, contributing to N-glycan 
variation. Varying residues between species include N-glycolylneuraminic acid 
(Neu5Gc), galactose (Gal), fucose (Fuc), N-Acetylneuraminic acid (Neu5Ac), xylose 
(Xyl), and mannose (Man). Since animal (mammalian) N-glycan structures are most 
similar to humans, mammalian cell platforms are the system of choice for the production 
of complex protein therapeutics or reagents. Humans generate antibodies to the Neu5Gc 
and Galα1-3Galβ1-(3)4GlcNAc (alpha-Gal) epitopes (shown by black arrows), making 
biologics with these structures more immunogenic.  
Source: Ghaderi et al., 2012 
 
Owing to the need for complex PTMs, ERTs are usually produced in mammalian 
cell lines. Currently, only a few mammalian cells have the ability to produce biologics 
with human-like N-glycans, including but not limited to, Chinese hamster ovary (CHO) 
cells, SP2/0 (murine myeloma), and NS0 cells (murine myeloma). However, selecting 
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host cells for biologic production requires more consideration than choosing between a 
platform with or without complex PTM capabilities. Human-like glycans produced by 
animal cells still exhibit differences that are immunogenic to humans. Specifically, 
humans produce antibodies to two structures commonly present on non-human 
mammalian cells, the Galα1-3Galβ1-(3)4GlcNAc (alpha-Gal) epitope and N-
glycolylneuraminic acid (Neu5Gc), a sialic acid (Ghaderi et al., 2012) (Figure 4). Over 
the past few years, research efforts have been put into engineering cell lines that mimic 
human glycosylation patterns, and reduce alpha-Gal and Neu5Gc. For example, the 
enzyme, cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), is 
responsible for catalyzing N-acetylneuraminic acid (Neu5Ac) to Neu5Gc and is active 
and highly expressed in mammals but deficient in humans (Xu et al., 2012). Gene editing 
can be utilized to knockout CMAH, removing the Neu5Gc epitope (Beaton et al., 2015). 
In addition, the gene, glycoprotein alpha-galactosyltransferase 1 (GGTA1), can also be 
knocked-out to remove the presence of the alpha-Gal epitope (Beaton et al., 2015).   
Currently, CHO cells are the workhorse of the biopharmaceutical industry, 
producing about 70% of the FDA-approved biologics on the market (Jayapal et al., 2007). 
The first commercial therapeutic protein, tissue plasminogen activator (tPA) was 
produced in CHO cells (Wurm, 2004). Ever since, CHO cells have gained increasing 
popularity for biologic production due to its FDA regulatory approval rate, ability to 
produce protein with human-like N-glycans, high protein production yields, and can 
quickly grow in serum-free media, high cell densities and large-scale bioreactors 
(Ghaderi et al., 2012). Proteins expressed in CHO expression systems are more 
  
10 
 
compatible with the human immune system compared to other mammalian cell lines due 
to their ability to modify proteins with human-like N-glycan residues (Ghaderi et al., 
2012). Although more compatible than most mammalian systems, CHO cells add the 
Neu5Gc and the alpha-Gal epitope to the recombinant protein which can result in an 
immunogenic response in humans (Ghaderi et al., 2012). CHO cells are also limited by 
phenotypic drift, affecting desired phenotypic properties of a clonal cell line including 
product quality, cell growth, and viability during the production process (Bandaranayake 
& Almo, 2014). 
Myeloma cells, such as SP2/0 and NS0, naturally secrete high amounts of 
antibodies, making them a logical host for protein manufacturing. Murine myeloma cells 
still make up the second most popular choice of mammalian expression platforms due to 
high regulatory approval of antibody therapeutics. Due to high regulatory approval, 
murine myeloma cells are known to produce some of the top-selling blockbuster 
therapeutics, including Remicade (infliximab), generating over $8.37 billion annually 
(Walsh, 2014).  Myeloma cells originate from immunoglobulin-producing tumor cells, 
but were genetically engineered to eliminate the production of its native immunoglobulin 
(Markusen & Robinson, 2013). As a result, the required machinery for protein production 
remains available for the manufacturing process of recombinant proteins. Together, 
SP2/0 and NS0 cells are the most popular antibody production platform due to their 
ability to produce high protein titers, add human α2-6 sialyl linkages, and have much 
higher sialylation compared to CHO cells (Ghaderi et al., 2012). In addition, murine 
myeloma cells are the fusion partner for antibody-producing hybridoma cell lines. 
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However, recombinant proteins expressed in myeloma cells are limited by higher levels 
of alpha-Gal and Neu5Gc compared to CHO, making myeloma products more 
immunogenic (Ghaderi et al., 2012). To prevent immunogenic responses, careful dosing 
of a myeloma-produced biologic is required (Ghaderi et al., 2012). With the high protein 
productivities and gene editing technology to remove or minimize immunogenicity, 
murine myeloma cell lines remain a top choice for recombinant protein production and 
still have the capability of producing high quality proteins for research applications.  
The traditional method to produce protein therapeutics is to express the 
therapeutic protein in a stable cell line. The protein therapeutic is usually encoded in 
genetic material with the sequences for the protein of interest and a selectable marker 
encoding a resistance gene. Due to increasing regulatory requirements, most biologic-
producing cell lines are usually selected using metabolic selection methods instead of 
antibiotic selection. The use of antibiotic resistant markers is discouraged for biologic 
production in order to avoid horizontal genetic transfer of antibiotic resistant genes to 
bacteria that may be present in the normal microflora or the environment (Mignon, 
Sodoyer, & Werle, 2015). The genetic material is transfected into the host cell and is 
subjected to rounds of selection pressure, giving a survival advantage to cells 
successfully transfected with the selectable marker (Wurm, 2004). A stable pool of 
successfully transfected cells will grow, expressing the protein of interest. Next, a single 
clonal cell expressing the recombinant protein is isolated into its own cell culture, usually 
performed in individual wells within a 96-well cell culture plate. Clonal cells are then 
expanded into larger culture volumes, where they can then be screened by various assays 
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to ensure that the recombinant protein is expressed. After confirmation that the clonal cell 
expresses the recombinant protein, the clone will be scaled up to liter-scale volumes in 
bioreactors. The cells and media are harvested days later after the start of a production 
run in the bioreactor. The collected harvest is later purified and stored for future use.  
One of the most commonly used metabolic selection methods to isolate a high-
expressing clone is Lonza’s glutamine synthetase (GS) system, which is the selection 
method for the manufacture of 29 FDA-approved therapeutics (Lai, Yang, & Ng, 2013).  
Glutamine is essential for cell growth and metabolism. The glutamine synthetase (GS) 
selection method utilizes mammalian cell’s dependence on glutamine for survival. In 
glutamine-free culture conditions, cells rely on GS, an enzyme which catalyzes the 
synthesis of glutamine from glutamate and ammonia. The method works best using host 
cells with low or no endogenous GS expression (e.g. murine myeloma cells), promoting 
survival of the cells successfully transfected with a genetic construct encoding glutamine 
synthetase and the recombinant protein of interest. The GS system can also be used to 
amplify recombinant protein expression by using methionine sulphoximine (MSX), an 
inhibitor of GS. The overexpression of the recombinant protein is the result of cellular 
survival mechanisms for adaptation to increasing selection stringency. Adaptation to 
selection pressure can be accomplished by gene amplification of the integrated vector, or 
more efficient transcription (Zhang, 2010). Usually, the GS selection marker and the 
recombinant protein are closely linked in the genetic construct allowing the recombinant 
protein to be co-amplified with GS. This is an effective selection method to use while the 
cells are recovering after transfection and during the cloning process.  
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With an increase in the number of novel therapeutics in our drug discovery 
pipeline, there is a high demand to produce a variety of recombinant proteins, including 
biologics and reagent proteins, for early-stage drug development projects. Currently, the 
main challenges of biotherapeutic and protein reagent production are the high cost, low 
production yields, and lengthy process of cell line development. For these reasons, most 
research efforts in protein production are focused on improving the speed of the 
production process and boosting the recombinant protein yield. Furthermore, some 
proteins are considered difficult-to-express because they may aggregate, demonstrate 
protein instability, or they could be modified without critical PTMS for proper 
functioning. Some proteins are also considered difficult-to-express if the expressed 
protein is toxic to the host cell. Lysosomal enzyme recombinant therapeutics fall under 
the difficult-to-express protein category for several reasons. First, it is estimated that only 
10-20% of the overexpressed lysosomal enzyme expressed is secreted, with the rest of the 
lysosomal enzymes localizing to the host cells’ lysosomes (Migani, Smales, & Bracewell, 
2017). This reduces the secreted protein yield available for harvesting and potentially 
causes a LSD within the production host itself. Various techniques are currently available 
to overcome some of the factors that cause a protein to be difficult-to-express. For 
example, a common issue during the protein production process is that a cell line can 
undergo cell death early during a production as a result of shear stress or nutrient 
deprivation, lowering the amount of cells available for protein production. To increase 
cell productivity, the cells can be co-transfected with the gene encoding the recombinant 
protein with an anti-apoptotic gene such as, Bcl-XL or Bcl-2, extending cell line viability. 
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However, the production of some difficult-to-express proteins may pose several different 
problems involving many cellular pathways that need to be adjusted. Instead of finding 
ways to implement many changes in the host cells’ biochemistry, it is faster and usually 
more effective to change expression platforms. Having multiple expression platforms is 
invaluable during cell line development process for efficient production of recombinant 
proteins. 
The goal of this project is to expand to our current expression systems for 
difficult-to-express proteins by developing a protein production platform using the SP2/0 
myeloma cell line as a host. By expanding our expression toolbox with high-expressing 
platforms, we can equip our protein production process with the tools and capability for 
diverse protein expression. Since the SP2/0 cell line is amongst the most commonly used 
cell lines for therapeutic and reagent protein production, developing a SP2/0 expression 
system may offer additional benefits to our recombinant protein production needs 
including: expression of difficult-to-express proteins, improving titers, and extending 
recombinant cell line stability. A lysosomal enzyme therapeutic candidate, a difficult-to-
express protein, was expressed in SP2/0 cells as a proof-of-concept for developing this 
protein expression platform. Using high-resolution imaging in conjunction with a GS 
selection method, we isolated a high-yielding SP2/0 clone. The bioprocess for the high-
yielding clone was optimized to establish a working SP2/0 protein production method, 
boost production titers, and maintain high cell viability during protein production. Using 
the optimized SP2/0 expression platform, milligram amounts of the ERT was generated 
for a series of assays for product quality characterization including its glycosylation 
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profile and cellular uptake.  
2.0 RESEARCH DESIGN AND METHODS  
 
2.1 Cell Culture 
 
SP2/0 cells were maintained in a proprietary myeloma medium (referred to in this 
paper as SP2/0-BMN media) supplemented with 8 mM GlutaMAX (Life Technologies, 
Grand Island, NY) in shake flasks. The SP2/0 cells were incubated at 37˚C, 125 RPM, 
and 8% CO2. Cell cultures were passaged 2-3 times a week, at a seeding density of 0.5 to 
2 x 10
6
 cells per mL. This maintenance culture was used for early experiments and 
transfections for this project where wild-type SP2/0 cells were needed. The cell culture 
was kept under 20 passages for the experiments. 
Primary human fibroblast cells with the lysosomal storage disease of interest 
(Coriell, Camden, NJ), were grown in DMEM with L-glutamine (ThermoFisher 
Scientific, Rockford, IL) supplemented with 15% fetal bovine serum (VWR, Radnor, 
PA). Cell cultures were passaged when cells reached 90% confluence, and were 
maintained in 150-cm
2
 tissue culture flasks (Corning, Manassas, VA) at incubation 
conditions of 37˚C and 5% CO2. All cells were kept under 20 passages for the 
experiments. 
2.2 Total Protein Extraction from Cell Lysates 
  
Total protein was extracted from cell lysates using the manufacturer’s instructions 
included with the Pro-Prep Protein Extraction Solution. The cell pellet was washed once 
in 1 X Dulbecco’s phosphate buffered saline (DPBS) (Corning) and removed after 
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centrifugation at 250 x g for 5 minutes. Excess DPBS wash was removed after a second 
round of centrifugation at 13,000 RPM for 30 seconds. The cell pellet was resuspended in 
400 µl prep protein extraction solution for approximately every 5 x 10
6
 cells. The cell and 
lysis buffer solution was then incubated at -20 ˚C for 20 minutes. After incubation, the 
cells were spun down at 13,000 RPM for 10 minutes. The supernatant, which contains the 
cell lysates, was carefully removed and stored in a separated microcentrifuge tube.   
2.3 BCA Assay  
 
A BCA assay (Pierce, Rockford, IL) was performed for each sample, using the 
manufacturer’s protocol, to estimate total protein concentration. Each sample was done in 
duplicate at three different dilutions, 2X, 5X, and 10X, plated at a volume of 10 µl per 
well in a 96 well plate. 24.5 ml Reagent A and 0.5 ml Reagent B were mixed and 
immediately added to each of the wells at a volume of 200 µl per well. Plates were 
incubated for 30 minutes at 37˚C then were immediately read using a plate reader at a 
wavelength of 562 nm. Each sample concentration was estimated using the average of the 
duplicate wells which were within range of the standard curve.  
2.4 Western Blots and Ponceau S Staining 
 
Protein samples, cell lysates, and media samples with secreted proteins were 
treated with NuPAGE 1X LDS buffer (Life Technologies, Carlsbad, CA). The protein 
samples were then denatured by heating at 95˚C for 10 minutes, and separated in 
NuPAGE 1.0 mm 4-12% Bis-Tris Gel (Life Technologies). The protein was transferred 
from the gel onto a nitrocellulose membrane using the iBlot 2 device (Life Technologies) 
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at 20V, for 7 minutes. Following the transfer, the membrane was stained using one 5 
minute wash of 1X Ponceau S stain in 5% acetic acid followed by two washes in 5% 
(v/v) acetic acid for 5 minutes each, then two washes in distilled water for 5 minutes 
each. The membrane was imaged using a photo scanner to provide an image of total 
protein, demonstrating equal loading. After imaging, the membrane was then washed in 
StartingBlock T20 (TBS) blocking buffer (Thermo Fisher Scientific) for 1 hour.  The 
primary antibodies (listed per experiment, with the exception of proprietary antibodies) 
were diluted at 1:1,000 in StartingBlock T20 (TBS) blocking buffer. The secondary 
antibodies (listed per experiment) were diluted to 1:5000 in StartingBlock T20 (TBS) 
blocking buffer. Blots were visualized by adding Western blue stabilized substrate for 
alkaline phosphatase (Promega, Madison, WI) or if using an IRDye 800CW antibody, 
imaged using the Odyssey CL Imaging system (LI-COR Lincoln, Nebraska).  
 
2.5 Development of a SP2/0 Cell Line Expressing an ERT as a Proof-of-Concept 
Model 
 
 
2.5.1 Testing the Glutamine Synthetase (GS) Selection System in SP2/0 Cells 
  
In order to determine whether expressing the GS gene can be used as an 
appropriate metabolic marker for successfully transfected SP2/0 cells, SP2/0 cell growth 
and viability were monitored in the presence and absence of glutamine. Three other cell 
lines were also tested for comparison. Each cell line was seeded into shake flasks with 
different proprietary basal media, each of which is optimal for cell viability and growth 
specific to each cell line. SP2/0 cells were seeded in SP2/0-BMN media. In total, four 
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different cell lines were tested: SP2/0, wild-type CHO, GSKO CHO cells, and SP2/0 cells 
transfected with a vector encoding GS. The flasks were seeded at a cell density of 5 x 10
5
 
cells per ml in 30 ml of basal media supplemented with 8 mM GlutaMAX and another 
flask with the same basal media but lacking glutamine. 1 ml sample was collected daily 
for 8 days to track viable cell density (viable cells/ml) and viability using the Vi-Cell XR 
cell counter (Beckman Coulter, Indianapolis, IN). In addition, 400 µl of the culture was 
pelleted by centrifugation at 250 x g for 5 minutes and stored at -80˚C until the all of the 
time point samples were collected and were ready for further experimentation. Protein 
from cell lysates were extracted using Pro-Prep Protein Extraction Solution (iNtRON 
Biotechnology Inc., Korea) and the western blot protocol as described previously. For the 
western blot, the gel was loaded with 15 µg protein per well. The glutamine synthetase 
was probed using the glutamine synthetase AB1055 monoclonal antibody (Novus 
Biologicals, Littleton, CO) diluted at 1:1,000 in StartingBlock T20 (TBS) blocking 
buffer. The primary antibodies were probed using anti-mouse IgG (H+L) AP Conjugate 
(Promega) diluted 1:5,000 in StartingBlock T20 (TBS) blocking buffer, and visualized by 
adding Western blue stabilized substrate for alkaline phosphatase (Promega). 
 
2.5.2 Stable Transfection of SP2/0 Cells 
             
100 µg plasmid DNA encoding the recombinant lysosomal enzyme and a 
glutamine synthetase (GS) selection marker was linearized at 37˚C overnight in 1X 
cutsmart buffer (New England Biolabs, Ipswich, MA) and 20U PvuI-HF (New England 
Biolabs). The linearized DNA was cleaned up using QiaQuick PCR cleanup kit (Qiagen, 
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Valencia, CA) using the spin column and centrifuge method detailed in the 
manufacturer's instructions. This linearized DNA was used for the stable transfection. 
One day before transfection, SP2/0 cells were counted using the Vi-Cell XR and were 
passaged to a viable cell density of 1 x 10
6
 cells/ml in SP2/0-BMN media supplemented 
with 8 mM GlutaMAX. The day of transfection, the culture cell density was counted 
using the Vi-Cell XR to calculate the volume of cell culture required for 2 x 10
6 
total 
cells, the amount of cells needed for transfection. 2 x 10
6 
cells were pelleted by 
centrifugation at 250 x g for 5 minutes. The cell pellet was resuspended in Hyclone 
Buffer EP (GE Healthcare, Gaithersburg, MD) and 20 µg of the linearized plasmid DNA 
to a final volume of 400 µl. The cell-DNA mixture was transferred into an OC-400 
processing assembly (Maxcyte, Gaithersburg, MD) then electroporated using the 
MaxCyte STX Scalable Transfection System and its SP2/0 electroporation program, the 
optimal voltage for SP2/0 cells pre-programed into the MaxCyte STX Scalable 
Transfection System. After electroporation, the cells were placed into an empty shake 
flask and recovered in a stationary incubator at 37˚C and 5% CO2 for 30 minutes. The 
cells were then resuspended in 13 ml of SP2/0-BMN media+8 mM GlutaMAX and 
incubated in a 37 ˚C stationary incubator overnight. One day after transfection, cells were 
pelleted by centrifugation at 250 x g for 5 minutes, then resuspended in a different 
proprietary media, SP2/0-BMN-2 glutamine-free media. The transfected cells were 
maintained in the stationary incubator until cell viability increased to 80%. The 
transfected cell population was maintained in glutamine-free SP2/0-BMN-2 media + 8 
mM GlutaMAX in volumes of 10 mL or less.       
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2.5.3 Screening the Transfected Pool and Clones for ERT Expression Using Western 
blots 
 
The transfected SP2/0 cells were tested to ensure that the cell population 
expressed the recombinant lysosomal enzyme. The transfected SP2/0 cell population was 
counted using the Vi-cell XR. 4 x 10
6 
cells were pelleted using the centrifuge at 250 x g 
for 5 minutes. The supernatant, containing the culture media and the secreted 
recombinant lysosomal enzyme was separated from the cell pellet and stored at -80˚C 
until needed for the enzyme activity assays or western blots. A western blot was 
performed to screen for the presence of the secreted recombinant enzyme using the 
protocol described previously. For this western blot, the gel was loaded with 15 µl of the 
supernatant and LDS mixture per well, each well containing a different clone sample. 
The secreted recombinant enzyme was probed using a proprietary antibody specific to the 
enzyme, which was diluted at 1:1,000 in StartingBlock T20 (TBS) blocking buffer. The 
primary antibody was probed using anti-rabbit IgG (Fc) AP Conjugate (Promega) diluted 
1:5,000 in StartingBlock T20 (TBS) blocking buffer, and visualized by adding Western 
blue stabilized substrate for alkaline phosphatase (Promega). The membrane was imaged 
using a photo scanner. 
2.5.4 Single Cell Isolation to Collect High-Expressing Clones 
  
Clones were isolated from the transfected cell population by limiting dilution. The 
clones were seeded and expanded in increasing volumes using an optimized post-
transfection method for SP2/0 cells which requires two different types of media 
(Supplementary Figure 1, Supplementary Figure 2, and Supplementary Figure 3). The 
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cells were diluted to a low cell concentration in SP2/0-BMN-2 glutamine-free media, and 
were seeded into each well in 96 well plates at one cell per well or 0.5 cells per well (one 
cell per two wells).  In order to track and document the growth from a single cell, a high-
resolution imaging instrument, the Cell Metric CLD (Solentim, UK), was used to image 
and monitor the growth of single cells after 2 hours, 24 hours, 4 days, 5 days, 7 days, 14 
days, and 19 days after plating. Wells that contained more than one cell per well were 
excluded from the clonal selection.  
The fastest growing clones were chosen for expansion. These 24 clones were 
expanded in increasing volumes in stationary incubation settings at 37˚C and 5% CO2. In 
small volumes of 2 mL or less, SP2/0-BMN-2 media was used. When a clonal colony 
was expanded to volume larger than 2 mL, SP2/0-BMN media was used. Clones were 
expanded in stationary incubation conditions until the cells reached a cell density of 2 x 
10
6 
cells per ml in 40 ml volume. Viable clones were then transferred to 25 ml shake 
flasks and were maintained at a cell density of 0.5-2 x 10
6
 cells/ml in SP2/0-BMN media. 
The viable clones were used for further experiments after a minimum of three rounds of 
passaging in with 96% viability or higher in shake flasks.  
2.5.5 Screening for the Top-Producing Clone 
 
 All clones that were able to scale up in volume and survive in shake flasks were 
seeded into separate flasks at 5 x 10
5
 cells/ml in 25 ml SP2/0-BMN media for an initial 
production run. 1 ml was taken from each cell culture at seven time points over the 
course of 10 days to monitor cell growth, viability, and lysosomal enzyme production. At 
the peak of cell growth and viability, day 8, a lysosomal enzyme activity assay was used 
  
22 
 
to quantify the amount of lysosomal enzyme produced by each clone. 
2.5.6 Recombinant Enzyme 4-Methylumbelliferone (4-MU) Activity Assay 
 
 To quantify the amount of active recombinant lysosomal enzyme produced from 
the transfected SP2/0 cells, a fluorescent plate-based 4-methylumbelliferone (4-MU) 
assay was used. Cell samples were pelleted in the centrifuge at 250 x g for 5 minutes. The 
supernatant, containing the secreted lysosomal enzyme, was separated into a fresh tube. 
The enzyme-media mixture was diluted 10 fold and 20 fold in a dilution buffer (5 mM 
sodium phosphate, 150 mM NaCl, 0.005% Tween 80, 0.1% BSA, pH=6.5) and plated in 
duplicate within a black flat-bottom 96-well plate. 90 µM of 4-MU conjugated substrate 
specific to the recombinant lysosomal enzyme, mixed with an assay buffer (50 mM 
sodium citrate, 125 mM NaCl, 0.5% Triton X 100, 0.1% BSA, 2 mM 4-MU, pH=4.5) 
then added to the plated samples. The plate was incubated at 37˚C for 40 minutes. After 
incubation, the reaction was stopped by adding 200 µl/well stop buffer solution (0.5 M 
glycine, 0.3M NaOH, pH 10.3). 4-MU-conjugated substrate cleavage by the lysosomal 
enzyme released fluorescent 4-MU which was measured using a fluorescent plate reader 
(Molecular Devices, Sunnyvale, CA) using excitation wavelength, 355 nm and emission 
wavelength 460 nm. In addition, fluorescent 4-MU was serially diluted to generate a 
standard curve in known concentrations to convert relative fluorescent units (RFU) to 4-
MU concentrations. A known concentration of a control lysosomal enzyme sample was 
used to convert the 4-MU concentrations to concentrations of the enzyme.  
2.5.7 Production Run of the Top Five Clones Expressing the Lysosomal Enzyme 
 
 The top five clones went through a second production run to ensure consistent 
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results with the previous production run. The top five clones were seeded into separate 
flasks at 5 x 10
5
 cells/ml in 25 ml SP2/0-BMN media. 1 ml sample of cell culture was 
collected daily for 8 days to monitor cell growth, viability, and lysosomal enzyme 
production. The clone capable of maintaining high viability and producing the highest 
amount of the lysosomal enzyme was considered the top clone from this experiment. This 
clone will be used for further characterization experiments.  
2.6 SP2/0 Cell line Characterizations of the Top-Producing Clone 
 
 
2.6.1 Screening Basal Media for the SP2/0-2H3 Clone 
 
 A seven-day production run of the SP2/0 clone with the highest expression of the 
lysosomal enzyme, clone SP2/0-2H3 was used to screen a panel of five proprietary 
serum-free basal media. Over the course of seven days in different media, cell growth, 
viability, and protein yields were observed for SP2/0-2H3. Clone SP2/0-2H3 was seeded 
at 5 x10
5
 cells per ml in a total volume of 25 ml of each of the different basal medium, 
Media A, Media B, Media C, Media D, or Media E. Each 25 ml culture was cultured in 
125 ml shake flasks and were incubated at 37˚C, 8% CO2, and 125 RPM. One ml culture 
sample was taken daily for seven days to count viable cell density (viable cells per ml) 
and cell viability using the Vi-Cell XR cell counter. The sample was also used to 
determine protein production yields by the enzyme activity assay described previously. 
This condition was done in two independent experiments with two technical replicates 
per independent experiment.  
2.6.2 Production Runs of Clone SP2/0-2H3 using Temperature Shifting 
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A popular approach to improving protein yields involves using a temperature 
shift, a method which slows cell growth to extend the cultivation process. During a 
temperature shift, mild hypothermia is induced to the cell cultures by shifting incubation 
temperature from 37˚C to a temperature a few degrees lower. To determine whether the 
induction of mild hypothermia improves protein production yields for clone SP2/0-2H3, 
six 250 ml shake flasks of the clone were seeded at 5 x10
5
 cells per ml in a total culture 
volume of 50 ml using the top performing media, determined previously. Each flask was 
incubated at 37˚C, 8% CO2, and 125 RPM, and later temperature shifted to 32˚C, 8% 
CO2, and 125 RPM on different days during the production run. Specifically, of the six 
flasks, one flask was not shifted and remained at 37˚C, one flask was temperature shifted 
day 0, and the remaining four flasks were temperature shifted either days 1, 2, 3, or day 4. 
1 ml samples were collected daily for 7 days to observe changes in cell growth, viability 
and protein yields in response to temperature shifting.  
2.6.3 Screening Myeloma Supplements for Improved Protein Production 
 
 A seven day production run of the SP2/0-2H3 clone was used to screen five 
commercial serum-free nutrient supplements formulated for improved protein production 
from myeloma cell hosts. Clone SP2/0-2H3 will be seeded at 5 x10
5
 cells per ml in a total 
volume of 50 ml in the best basal media as determined previously. The cultures were 
incubated in 250 ml shake flasks at 37˚C, 8% CO2, and 125 RPM. For feed strategy 1, 
cell cultures were fed with 5% volume feed on day 0, 10% volume feed on day 3, and 
10% volume feed on day 5 with three commercial supplements. For feed strategy 2, cell 
cultures were fed with 10% volume feed on day 3 and 10% volume feed on day 5 with 
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five commercial supplements.  Cell culture samples were taken daily for seven days to 
measure viable cell density, cell viability, and protein yield. Each condition was done in 
two independent experiments.  
2.6.4 Gene Amplification of SP2/0-2H3 Clone Using Methionine Sulphoximine 
(MSX) Selection Pressure 
 
 To further boost protein yields for clone SP2/0-2H3, methionine sulphoximine, an 
inhibitor of GS, was added to the cell cultures to amplify the copy number of the 
integrated plasmid encoding the protein of interest. The top performing clone, SP2/0-
2H3, was seeded into five 250 ml shake flasks, in a 50 ml volume with a cell density of 5 
x10
5
 cells per ml in the top performing media determined previously. Each flask 
contained a different concentration of MSX: no MSX, 5 µM, 10 µM, 20 µM, or 50 µM 
MSX. The cells were passaged every 2-3 days to 5 x10
5
 cells per ml for three weeks. 
Passaging was performed by pelleting cells by centrifugation at 250 x g for 5 minutes, 
and resuspending the cell pellet in fresh Media A supplemented with the same MSX 
concentration. Gene amplification was checked by western blot after three weeks using 
the protocol described previously. Each well was loaded with 6 µg total protein, 
determined by a BCA using the protocol described previously. The nitrocellulose 
membrane was probed with the glutamine synthetase AB1055 monoclonal antibody and 
detected using the anti-mouse IgG (H+L) AP conjugate antibody (Promega). 
 After three weeks of selection pressure under different concentrations of MSX, 
the SP2/0-2H3 cells were seeded at a cell density of 5 x10
5
 cells per ml in 50 ml fresh 
MSX-free media for a production run. Over the course of the seven day production run, 
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cell culture samples were taken daily to measure viable cell density, cell viability and 
protein yield. Each production run was done in two independent experiments, with two 
technical replicates per independent experiment.  
2.7 Large Scale Recombinant Protein Production Run 
 
 The SP2/0-2H3 clone was scaled up to two liters with the goal of producing at 
least milligrams to gram quantities of the recombinant lysosomal enzyme. To produce the 
recombinant enzyme, a production run was done using the 50 µM MSX-pressured SP2/0-
2H3 cell line and the optimal bioprocess conditions determined previously including: 
basal media, supplement, and temperature. The 50 µM MSX-pressured SP2/0-2H3 clone 
was scaled up to 2 liters in Media A and seeded at 5 x10
5
 cells per ml in a 5L shake flask. 
On days 3 and 5, 10% volume Feed 2 was added to the culture. On day 6, the protein was 
harvested from the cell culture by centrifugation at 250 x g for 15 minutes. The 
supernatant containing the recombinant protein was filtered using a vacuum filter, 
HarvestMax-100 (Marin Scientific Development Company, Greenbrae, CA), to remove 
the remaining cells and cell debris for fluid suitable for chromatography.  
2.8 Recombinant Protein Purification 
 
 The filtered supernatant containing the recombinant protein was thawed from -
80˚C storage. The recombinant protein was diluted with the half the volume of 20 mM 
Tris and was adjusted to pH 7.3. The recombinant protein was loaded into a GigaCap Q-
650M column (Sigma) and washed with 20 mM Tris. The purified samples were eluted 
with 20 mM Tris 1M NaCl buffer. The recombinant protein was further concentrated 
using Amplicon Ultra 0.5 ml Centrifugal Filters (Millipore, Billerica, Massachusetts) and 
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the manufacturer instructions. 
2.9 ELISA Quantification of the Recombinant Protein 
 One day before performing the sandwich ELISA, wells of 96-well plates were 
coated with 15 µg/ml of antibody specific to the recombinant enzyme, diluted in coating 
buffer (0.05 M carbonate, pH9.6) and incubated at 4˚C overnight. Approximately 16 
hours later, the wells were washed three times with TBST, then incubated in blocking 
buffer (6% BSA in TBST) for 1 hour. After blocking, and after each step of the ELISA, 
the wells were washed three times with TBST. The wells were then incubated with 3125 
pg/well of recombinant protein produced from CHO cells or SP2/0 cell hosts, diluted in 
blocking buffer for 2 hours. The recombinant protein was probed in a 1 hour room 
temperature incubation with 50 µL 1 µg/ml of a biotin-conjugated antibody diluted in 
blocking buffer. The biotin was bound by 100 µL Streptavidin-HRP (R and D Systems, 
Minneapolis, MN), which was diluted 1:200 in blocking buffer and incubated for 1 hour. 
Binding of the biotin-conjugated antibody was detected using a QuantaBlu Fluorogenic 
Peroxidase Substrate kit (ThermoFisher Scientific) according to manufacturer 
instructions.  
2.10 Protein Quality Comparison Studies 
 
2.10.1 Passaging to Determine SP2/0-2H3 Cell Line Stability 
 
 The top five SP2/0 clones with the highest recombinant enzyme production were 
determined by the enzyme activity assay. The top clone was passaged 2-3 times a week. 
Cells were passaged down to a viable cell density of 5 x10
5
 cells per ml in a total volume 
of 25 ml. Four days after passaging, one ml of each cell culture was kept for the 4-MU 
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enzyme activity assay. Enzyme activity was tracked over the course of 30 passages. 
These cultures were maintained in Media A, the best basal media determined by the 
media screen.  
 
2.10.2 Uptake Assays  
 Primary human fibroblast cells were seeded into 24-well culture plates (Corning) 
at 150,000 cells/well and were grown for 24 hours at 37˚C and 5% CO2 to reach 
approximately 90% confluency. To generate a dose-response curve, the cells were then 
dosed with six concentrations of recombinant protein produced from CHO cells or the 
same recombinant protein expressed in SP2/0 cells. Doses of the recombinant protein 
were diluted with uptake medium (DMEM with L-glutamine supplemented with 0.5 
mg/ml BSA and 1 mM HEPES). In addition, 5 mM M6P (Sigma) was added to some 
wells as a competitive inhibitor to the recombinant protein drug. Each well containing the 
recombinant protein therapeutic and for some wells, M6P, were incubated at 37˚C and 
5% CO2 for 4 hours. After incubation, the cells were washed twice with DPBS, and lysed 
by shaking for 10 minutes at room temperature in 100 µL Mammalian Protein Extraction 
Reagent (M-PER) (ThermoFisher Scientific) supplemented with 1x protease inhibitor 
cocktail (Sigma). The cell debris from the lysates was removed by centrifugation at 
14,000 x g, 10 minutes, and 4 ˚C. The recombinant enzyme activity in the cell lysates 
were measured using the recombinant enzyme 6-HMU assay. 
2.10.3 6-HMU Enzyme Assay 
 Assay standards, 6-HMU, and recombinant enzyme controls, were diluted in M-
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PER. 30 µL of lysate samples from the uptake assays, controls, and standards were plated 
per well. The enzyme reaction was initiated by adding 30 µL mixture of 31.25 µM 6-
HMU conjugated substrate in assay buffer (0.1/0.2 M citrate phosphate buffer, sodium 
taurocholate, and sodium oleate, pH 4.4) to each sample. The reactions were incubated at 
37˚C for one hour. The reaction was stopped with 200 µL stop buffer (0.5 M glycine, 0.3 
M NaOH, pH 10.3). Fluorescence was measured with a plate reader (Molecular Devices, 
Sunnyvale, CA), using excitation wavelength, 355 nm and emission wavelength 460 nm. 
Dose response curves were fit using Michaelis-Menten in Prism version 7.02 (Graphpad 
Software Inc., La Jolla, CA), where KM and Vmax values were calculated using that curve.  
2.10.4 CI-M6PR Binding Assay 
 
 Cation-independent mannose-6-phosphate receptor (CI-M6PR) was diluted to 4 
µg/mL in coating buffer (100 mM Carbonate/bicarbonate buffer). 100 µL of CI-M6PR at 
µg/mL was immobilized to the wells of a black FluoroNunc MaxiSorp 96 well plate. The 
plate was incubated at 4˚C overnight. Wells of the plate were washed three times with 
wash buffer (PBS + 0.05% Tween 20), then blocked with 100 µL per well of SuperBlock 
T20 (PBS) Blocking Buffer (ThermoFisher Scientific) for one hour. Blocking buffer was 
removed by washing three times with wash buffer. CHO-produced ERT and SP2/0-
produced ERT were diluted to 100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.125 nM, 
1.56 nM, and 0 nM. 50 µL of each sample was added to the plate, and incubated for two 
hours at room temperature. After incubation, the plate was washed three times with wash 
buffer. 4-MU conjugated ERT substrate was diluted to 1.8 mM in assay buffer (50mM 
Citrate / 125mM NaCl / 0.5% Triton X-100, pH 4.5). 50 µL 4-MU substrate solution was 
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added to the receptor coated plate and incubated at 30 minutes for 37˚C. At the end of the 
incubation period, 200 µL stop buffer (0.5M Glycine, 0.3 M NaOH, pH 10.5) was added 
per well. 4-MU fluorescence was released upon cleavage of the 4-MU-conjugated 
substrate by the ERT. Fluorescence was measured using a plate reader (Molecular 
Devices) using excitation wavelength, 366 nm and emission wavelength 446 nm. 
 
2.10.5 Comparison of ERT Half-life Using the 6-HMU Enzyme Activity Assay and 
Western Blot 
  
 Primary human fibroblast cells were seeded into 24-well culture plates (Corning) 
at 150,000 cells/well and were grown for 24 hours at 37˚C and 5% CO2 to reach 
approximately 90% confluency. The CHO and SP2/0-produced ERTs were diluted to 50 
nM in uptake medium (DMEM with L-glutamine (ThermoFisher Scientific) 
supplemented with 0.5 mg/ml BSA and 1 mM HEPES). The fibroblasts were dosed with 
500 µL of the 50 nM ERT produced from CHO or SP2/0 hosts. For each time point, the 
SP2/0-produced ERT, CHO-produced ERT and uptake media were dosed to the 
fibroblasts in duplicate. Four hours after ERT dosing, the ERT was removed from the 
fibroblasts by washing wells once with DPBS. One mL DPBS media with L-glutamine 
and 15% FBS was added to the wells then incubated in a stationary incubator at 37˚C and 
5% CO2. The 0 hour time point sample was taken immediately after the four hour 
incubation dose. Five additional time points were collected at 24 hours, 48 hours, 72 
hours, 120 hours, and 168 hours. Each sample was harvested by washing cells twice with 
DPBS, then lysing using 100 µL M-PER supplemented with 1X protease inhibitor 
cocktail and shaking for 10 minutes. Samples were stored at -80˚C until needed for 
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analysis by the 6-HMU enzyme activity assay and western blot. The western blot was 
performed using the methods described previously. A proprietary monoclonal antibody 
specific to the ERT was used as a primary antibody, diluted 1:1,000 in blocking buffer. 
The primary antibody was probed using a secondary antibody, IRDye 800CW Goat anti-
mouse (LI-COR) diluted 1:5,000 in blocking buffer and detected using the Odyssey 
Imaging System (LI-COR).  
3.0 RESULTS 
 
3.1 Development of a SP2/0 Expression Platform for ERT Production 
 
The first goal of this project was to build a model SP2/0 expression platform for 
difficult-to-express proteins. For this project, a difficult-to-express human lysosomal 
enzyme that could potentially be used as an enzyme replacement therapy (ERT), was 
expressed in the SP2/0 cells as a proof-of-concept model. Compared to CHO cells, SP2/0 
cells have low endogenous GS expression, making the GS selection system (Lonza) ideal 
for selection of successfully transfected cells (Yazaki et al, 2004). To build a stable cell 
line, SP2/0 cells were transfected with a linearized plasmid encoding the GS and ERT 
gene. To select for successfully transfected cells, glutamine was removed from the media, 
forcing cells to rely on the incorporation of the transfected GS gene to convert glutamate 
and ammonia into glutamine.  
To verify that the endogenous levels of GS in SP2/0 cells is insufficient for cell 
division, cell growth, and viability, SP2/0 cell cultures were tracked over the course of 6 
days in glutamine supplemented and glutamine-free conditions (Figure 5). In addition to 
  
32 
 
the SP2/0 cells, other cell lines with varying levels of endogenous GS expression were 
tested in glutamine-free and glutamine supplemented conditions. In glutamine 
supplemented conditions, cell growth was constant and maintained high percent viability 
(over 80 percent viability) until it reached maximum cell capacity within the culture 
vessel, seen on day 5. In the absence of glutamine, a cell line without endogenous GS, the 
GS knockout CHO (GSKO) cells, and the cell line with low endogenous GS levels, SP2/0 
cells, were unable to survive, dropping below 50% viability by day 6, and halted cell 
growth immediately after removing glutamine (Figure 5). The only cell lines capable of 
healthy cell division and maintenance of high viability in glutamine-free media were the 
wild-type CHO cells, which are known to express higher levels of endogenous GS 
compared to SP2/0, and the SP2/0 cell line transfected with the plasmid encoding the 
ERT and selectable marker (SP2/0-GS-ERT). Furthermore, after only four passages of 
SP2/0 cells in glutamine-free media, cell viability dropped below 4% (data not shown). 
These results are consistent with literature review, demonstrating that low level of 
endogenous GS is not sufficient for survival in glutamine-free conditions, making the GS 
selection system a logical choice for selection of successfully transfected cells.  
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Figure 5. The effect of glutamine-free media on cell growth and viability 
 
Suspension adapted CHO cells, SP2/0 cells, GS knockout CHO cells, and SP2/0-GS-ERT 
cells (transfected with a plasmid encoding the GS selection marker and a gene encoding 
the ERT) were tested in glutamine-free media or the same media supplemented with 8 
mM GlutaMAX. 1 ml sample from each cell culture was collected daily to determine cell 
growth and viability over the course of 6 days. Error bars represent a variability of two 
biological replicates.  
 
To confirm the GS phenotype of the CHO, GSKO CHO, SP2/0, and SP2/0-GS-
ERT cell lines, cell lysates from the four cell lines and NS0 cells were run on a western 
blot to observe GS expression levels. The western blot results demonstrate that the CHO 
cells and SP2/0-GS-ERT express high levels of GS, whereas SP2/0 cells have lower 
endogenous levels of GS compared to CHO, and the GSKO CHO and NS0 cells did not 
express GS (Figure 6). Together, the western blot along with the growth and viability 
data indicate that the low endogenous GS levels in SP2/0 cells are insufficient for cell 
division or healthy metabolism in the absence of glutamine. To rescue this phenotype, 
exogenous GS is required to increase GS levels in SP2/0 cells for survival in glutamine-
free conditions. This confirms that the GS selection method can be used to isolate 
successfully transfected clones which express the ERT.  
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Figure 6. Endogenous glutamine synthetase in different cell types 
 
15 µg total protein from cell lysates of SP2/0, SP2/0-GS, NS0, CHO-S, and GS knockout 
CHO cells (GSKO CHO) cells were loaded into each well. A Ponceau staining of the 
membrane (left) was used to demonstrate equal loading. The western blot (right) displays 
endogenous expression levels of glutamine synthetase (GS) of various cell lines. 
  
To verify that the ERT is expressed in the transfected SP2/0 cells, the presence of 
the lysosomal enzyme was tested by western blot. Since the recombinant lysosomal 
enzyme is secreted from the cell, enzyme was harvested by removing the cell pellet from 
the media. Results demonstrate that the lysosomal enzyme was expressed in the 
transfected SP2/0 cell population. The SP2/0 cells continued to express the lysosomal 
enzyme after passaging the transfected SP2/0 cells in glutamine-free media for over two 
weeks, indicating that the plasmid was successfully integrated into the host genome, and 
was not expressed transiently.   
 After verifying that the transfected SP2/0 population stably expresses the 
transfected plasmid, single cells from the transfected population were isolated to limit 
genetic variation, a factor which could affect recombinant protein titers after several 
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passages. To do this, single cells were isolated by limiting dilution, and were plated 1 cell 
per well or 0.5 cells per well (one cell every other well) in 96-well plates. To eliminate 
wells that contained more than one cell per well, the plated cells were checked using the 
Cell Metric high-resolution imaging system. Wells with more than one cell per well were 
eliminated from clonal analysis. Of the wells which contained one cell per well, photo 
images were collected to demonstrate monoclonality (Figure 7). The most critical time 
points for clonal imaging are at 2-3 hours and 24 hours post-seeding. Imaging 2 hours 
post-seeding allows cells to settle into the well, reducing any cell migration while 
suspended in the media. The 24-hour time point is also an important time point as it 
provides photo evidence of the first cell division.  
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Figure 7. Example of monitoring transfected SP2/0 clones by high-resolution 
imaging 
 
Transfected SP2/0 cells capable of surviving in glutamine-free media were plated into 96-
well plates and monitored using a high-resolution imaging system. Cell growth was 
monitored for all clones for 19 days. An overview of the entire well is imaged by the 
imaging system (top image, well timeline) as well as a 10X magnification image of the 
entire well for each time point. Upon identification of a single cell in a well, the cell was 
marked clonal on the imaging program, allowing the software to compile photos of the 
same spot in the well for the duration of the cloning procedure (bottom images).  
 
 
 Out of the clones that derived from a single cell, the 24 fastest growing clones 
were screened for recombinant protein expression. The 24 clones were expanded in 
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increasing volumes, maintaining the viable cell density between 0.5 million cells per ml 
and two million cells per ml. Of the 24 clones, 7 clones were not able to expand to a 25 
ml culture volume, due to low viability or growth impairment. The remaining 17 clones 
were screened for expression of the recombinant enzyme by western blot, indicating 
successful integration of the transfected plasmid into the host genome. Out of the 17 
clones, four clones, 2F1, 257, 2D6, and 1H7, did not express the recombinant enzyme, 
and two clones 1C7 and 1B8 expressed low levels of the recombinant enzyme (Figure 8).  
 
 
Figure 8. Screening SP2/0 clones for expression of the lysosomal enzyme 
 
Culture media samples were harvested from each clone and were screened for the 
secretion of the recombinant lysosomal enzyme by western blotting. The lysosomal 
enzyme is expressed at 68 kDa, as seen by the positive control sample. Out the clones 
screened, clones 257, 2F1, 2D6, and 1H7 did not express the lysosomal enzyme.  
 
The remaining 13 clones were passaged about four times to restore normal cell 
growth and improve viability to a minimum of 90%. Although the western blot confirmed 
that the clones express the recombinant enzyme, its analysis is limited since it does not 
provide any information about the enzymatic activity or quantity of the enzyme 
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produced. To determine which of the 13 clones have the highest production yield of the 
active enzyme, small scale production runs of the 13 clones were used to produce the 
recombinant protein. While the clones showed varying rates of cell growth, most clones 
maintained at least 70 percent viability by day 8 (Figure 9). To quantify the amount of 
active recombinant enzyme produced by each clone, a plate-based 4-MU enzyme activity 
assay was used. This production screen identified clone 2H3 as the highest producing 
clone and the clone capable of maintaining at least 80 percent viability until day 8. 
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Figure 9. First clone screen: Recombinant enzyme production run using the GS-
ERT transfected SP2/0 clones 
Shake flasks were seeded at 5 x 10
5
 cells/ml in a total volume of 25 ml. At seven 
different time points during the production run, a sample from each cell culture was 
collected to monitor cell viability (A) and growth (B) during the production run. On day 
8, the day of highest cell density, a sample was collected to quantify the amount of 
lysosomal enzyme produced by each clone using a 4-MU enzyme activity assay (C).  
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 To confirm that clone 2H3 is the top producing clone, a second production run 
was done using the top five clones with the best production yields determined by the 
initial production run. The same procedure was used as the first production run except 
that 10% volume of supplemental nutrient feed was added to the clones on day 3. Adding 
the cell supplement improved the rate of cell growth for all clones, maximizing cell 
growth at day 5 instead of day 8 (Figure 10). The culture media from each flask was 
analyzed to quantify the amount of active lysosomal enzyme produced. Consistent with 
the previous experiment, clone 2H3 yielded a higher amount of active lysosomal enzyme 
and was considered the best production clone (Figure 10).  
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Figure 10. Second clone screen: Lysosomal enzyme production run using the 5 top-
producing clones 
A seven-day production run was used to confirm which clones yield the highest 
recombinant protein titers. Using the top five producing clones from the previous screen, 
shake flasks were seeded at 5 x 10
5
 cells/ml in a total volume of 25 ml. A sample of each 
cell culture was collected daily to monitor cell viability (A), growth (B) and production 
titer of the active recombinant enzyme (C). Each point represents one independent 
experiment.  
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3.2 Bioprocess Studies for the SP2/0 Cell Line  
 
 
To establish a working protein production protocol for the top producing SP2/0 
clone, a few characterization studies were done to optimize media, incubation 
temperature, and nutrient feed for improved protein productivity. 
3.2.1 Basal Media Screen 
 
 Generally, basal media is one of the most important components of cell culture 
optimization process since it is key source of nutrients to the cells, directly affecting cell 
viability and growth. The first cell line characterization study for this project screened a 
panel of five serum-free myeloma or hybridoma specific media for optimal viability, cell 
growth, and productivity. Shake flasks were seeded at 5 x 10
5
 cells per ml in a 50 ml 
volume, each with different media. Out of the five different media types, Media A was 
able to support rapid cell growth and maintain high cell density during the production run 
up to day 6 (Figure 11A and B). In addition to supporting fast growth and cell health, 
using Media A yielded the highest amount of the recombinant lysosomal enzyme (Figure 
11C). Since Media A was the best performing media to maintain cell health and 
recombinant protein production, this media will be used for the rest of the 
characterization experiments for the SP2/0-2H3 clone.   
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Figure 11. Screen of serum-free basal medium panel for SP2/0 clone 2H3 
A production run for the lysosomal enzyme was done using SP2/0 clone 2H3. Samples 
were collected daily for 7 days to track cell viability (A) and growth (B). On day 5, the 
day of the highest cell density and percent viability (over 80% viable), the active 
recombinant enzyme was quantified (C). Each bar represents the mean of two 
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independent experiments. Error bars represents range in variability of two biological 
replicates, each of which represent the average of two technical replicates.  
 
3.2.2 Temperature Shifting with SP2/0 Clone 
 
A widely used technique to boost protein productivity in CHO cells during the 
production process is temperature shifting, where mild-hypothermia is induced to 
suppress cell growth and glucose consumption while enhancing protein productivity 
(Furukawa & Ohsuye, 1998; Kumar, Gammell, Meleady, Henry, & Clynes, 2008) and 
extending cell viability (Moore et al., 1997). When cell cultures are temperature shifted, 
the incubation temperature is reduced from 37˚C to a few degrees lower. The effect of 
temperature shifting is different per cell line and can also have varying effects between 
different clones (Yoon, Hwang, & Lee, 2004). Unlike CHO cells which generally have a 
positive response to temperature shifting, there are varying reports on how temperature 
shifting affects productivity and metabolism in hybridoma cells (myeloma cell fused with 
a B-cell) (Furukawa et al, 1998, Mason, 2014). To observe whether production of our 
recombinant enzyme from the SP2/0-2H3 clone can be improved using a temperature 
shift, shake flasks at a 50 ml volume were seeded at the same cell density in Media A. 
Shake flasks were either temperature shifted and incubated at 32˚C a specific day during 
the production run or remained at 37˚C. When temperature shifting the SP2/0-2H3 cells 
line early during the production run (days 0, 1, or 2), cell growth increased at a steady 
rate and maintained high percent viability through the entire duration of the production 
run (Figure 12A and B). In comparison, the flasks that were temperature shifted later in 
the production run (days 3 and 4) reached the maximum cell density, resulting in a drop 
in percent viability. These results were reflected in protein productivity. By temperature 
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shifting early into the production run, clone 2H3 was able to reach over 18 mg/L, 
compared to the shifting late into the production run, which was only able to yield 
between 11 and 14.9 mg/L (Figure 12C). These results suggest that temperature shifting 
at day 0 can be used to maintain high viability and higher titers.  
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Figure 12. The effects of temperature shifting on clone SP2/0-2H3 
 
Shake flasks were seeded at 5 x 10
5
 cells/ml and were sampled and counted daily for 7 
days to track viability (A) and cell growth (B). Samples were collected day 0 and days 3-
7 to quantify lysosomal protein production during the production run (C). Each data point 
represents one biological replicate. 
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3.2.3 Nutrient Feed Optimization 
 
 Developing a feeding strategy is one of the main optimizations for fed-batch 
processes. In a fed batch process, the basal media supports initial cell growth, and 
additional nutrient feed is added to replenish the consumed nutrients, maximize 
productivity and extend the production phase.  A general feed strategy method for fed-
batch cultures, feed strategy 1, was a previously used method for fed batch cultures in the 
lab. In feed strategy 1, 5% volume feed was administered to the cultures on day 0, and 
10% volume feed on days 3 and 5. Cell cultures were assessed for improved productivity 
using three different nutrient feeds. When feeding strategy 1 was used, productivity was 
improved slightly (Figure 13). Using feed strategy 1, the culture without feed reached an 
average titer of 15.4 mg/L, while adding feed 2 improved the titer to an average of 23.1 
mg/L. Although this is an improvement in titer, it is also known that protein production 
from fed-batch processes can be limited when the cultures are over supplied with 
nutrients (Gorfien, Paul, Judd, Tescione, & Jayme, 2003). When a culture has excess 
nutrients, metabolic byproducts can accumulate, increasing cellular toxicity and stunting 
cell growth (Gorfien et al., 2003). If this was the case for feed strategy 1, a new feeding 
strategy needed to be employed to overcome that limitation. To create a strategy that 
reduces supplementation, feed strategy 2 was used. For feed strategy 2, cultures were fed 
with 10% volume feed on days 3 and 5 without the day 0 feed. As a result of changing 
feed strategy, productivity increased from an average titer of 17.7 mg/L to 37.8 mg/L and 
23.1 mg/L to 46.9 mg/L for feed 1 and feed 2 respectively. Overall, feed 2 was capable of 
reaching the highest product yield using feed strategy 2, reaching an average of 46.9 
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mg/L compared to feed 2, feed, 3 and the control culture without feed which reached an 
average titer of 37.8 mg/L, 0.771 mg/L, and 16.9 mg/L respectively. These results 
indicate that both the nutrient feed and the strategy are important optimization parameters 
for improving protein titers.  
 
Figure 13. The effect of feeding strategy on protein productivity 
 
Three different nutrient feeds were administered to SP2/0 clone 2H3 using either feed 
strategy 1 (5% volume feed on day 0, and 10% volume feed on days 3 and 5) or feed 
strategy 2 (10% volume feed on days 3 and 5). On the last day of the production run, day 
7, the recombinant protein activity was measured. Error bars represent two biological 
replicates.  
  
Since feed strategy 2 had the most success in boosting protein productivity, 
strategy 2 was used to screen two additional supplements to identify other nutrient feed 
candidates at a 50 ml scale. All nutrient feed, with the exception of feed 3, was able to 
extend high viability past day 5 compared to the control (Figure 14A).  In addition, all 
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feed with the exception of feed 3, increased viable cell density (Figure 14B). As a result 
of extending high viability during the production run and increasing the cell density, feed 
1, 2, 4, and 5 yielded higher titers than the control. Of the four supplements that improved 
protein production, two feeds were high performing, feed 2 and 5. Compared to the 
control which yielded an average titer of 16.9 mg/L by day 7, feed 2 and 5 increased the 
average titer to 46.9 mg/L and 47.1 mg/L respectively (Figure 14C). It should also be 
noted that recombinant protein titer for each nutrient feed may reach its maximum titer at 
different days during the production run. For example, where feeds 1, 2 and 5 reached 
maximum titer at day 7, feed 4 reached its maximum titer at day 6 yielding 41.9 mg/L. 
When optimizing nutrient feed, the protein titers should be measured the last few days of 
the production run to ensure that the recombinant proteins are harvested on their peak day 
during the production run. Using this optimization method, two nutrient feeds that 
doubled average protein production were quickly identified.  
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Figure 14. Screening glutamine-free nutrient feed for SP2/0 clone 2H3 
Ten percent volume of five nutrient feeds was administered to SP2/0 clone 2H3 
production cultures on days 3 and 5. Over the course of 7 days, culture viability (A), cell 
density (cell growth) (B), and protein production (enzyme activity) (C) were measured to 
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identify nutrient feeds that support robust growth and improved production. Error bars 
represent the range of two biological replicates. 
3.2.4 Amplification of the Expression Vector using GS-based MSX Selection  
 A widely-used method to amplify protein production from industrial cell lines is 
to amplify copy number of the gene encoding the recombinant protein. The GS selection 
marker is known to be a useful target for gene amplification (Wilson, 1993). Adding 
MSX to the cell culture acts as a selective pressure, requiring the cells to overexpress or 
amplify the GS gene along with the recombinant protein in the same vector construct. 
Cell colonies resistant to the MSX selective pressure are known to amplify the GS gene 
copy number up to 10 copies in a single round of selection (Wilson, 1993). The GS-MSX 
selection pressure method was used to increase expression of the GS along with the 
recombinant lysosomal enzyme stably integrated into the SP2/0-2H3 clone. The SP2/0 
clone 2H3 was pressured in four different concentrations of MSX for three weeks. As 
seen in the western blot images in Figure 15, GS expression of SP2/0 clone 2H3 
increased, along with the recombinant protein, as the concentration of MSX increased. 
Results of this experiment indicate that endogenous GS expression levels were 
successfully increased in response to MSX selection pressure. Since the recombinant 
lysosomal enzyme in the same expression vector was also co-amplified, these results 
indicate that the GS-MSX selection can be successfully used to increase protein 
production within three weeks.       
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Figure 15. Amplification the recombinant protein expression in clone 2H3 by adding 
MSX 
SP2/0 clone 2H3 was pressured in methionine sulphoximine (MSX) concentrations at 
either 5 µM, 10 µM, 20 µM, 50 µM, or no MSX for three weeks. 5.5 µg protein from 
MSX-pressured cells lysates were separated on an SDS-PAGE gel and were blotted onto 
a nitrocellulose membrane. Total protein load is visualized with a Ponceau-S stain (left) 
while GS and the recombinant protein were probed with either an anti-glutamine 
synthetase antibody or an antibody specific to the recombinant (right). The asterisk (*) 
indicates a nonspecific band.  
  
Although an increase in recombinant enzyme expression was previously shown 
by western blot, the western blot analysis cannot provide any information about enzyme 
activity or cellular health during protein production. To determine the quantity of the 
active recombinant enzyme that can be harvested from the MSX-pressured SP2/0 clone, a 
seven-day production run of MSX-pressured SP2/0 clone was performed. During the 
production run, percent viability was not dependent on MSX selection pressure (Figure 
16A). By day 5 all cell cultures started to decrease in viability regardless of MSX 
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concentration. When a higher concentration of MSX was used to pressure the cells, the 
maximum cell density was reduced (Figure 16B). Although cell density was lowered as a 
result of higher MSX concentration, this did not translate to a lower amount of 
recombinant protein. The production titers increased incrementally with MSX 
concentrations up to 50 µM. On day 5, the day before the viability and cell density 
dropped, each sample pressured with MSX was assayed to determine the recombinant 
protein titers. The cells pressured with 50 µM MSX were capable of reaching the highest 
average active recombinant protein titer, 35.9 mg/L, compared to the control, which 
reached 8.1 mg/L (Figure 16C). Using this method to increase protein productivity took 
three weeks, but was effective and would not require many supplements for large scale 
production. 
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Figure 16. MSX-amplified GS-ERT expression vector in clone 2H3 raises 
productivity 
SP2/0 clone 2H3 was pressured in methionine sulphoximine (MSX) concentrations at 
either 5 µM, 10 µM, 20 µM, 50 µM, or no MSX for three weeks. Shake flasks were 
seeded at 0.5 million cells per ml and sampled daily to monitor cell health including 
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viability and growth (A and B). On day 5 of the production run, the last day before a 
decrease in cell viability, protein production titers were measured by an enzyme activity 
assay (C). As concentrations of MSX selection pressure increased, protein titers 
increased. Error bars represent variation of two biological replicates, each of which was 
done in duplicate. 
 
 
Stable cell lines are characterized as cells that have the ability to maintain 
constant protein production over a long period of time. However, literature reports 
demonstrate that recombinant protein production can be affected by long-term culture of 
the stable cell lines. After a number of cell generations, cell line characteristics including 
cell morphology and growth rates are altered due to genetic variation. Changes in stable 
cell line characteristics ultimately lower recombinant protein expression and affect 
protein quality. The number of passages, or number of subculturing cells from one vessel 
to another vessel in fresh growth medium, is commonly kept under 20 passages to ensure 
cell line stability. To ensure that the top clone can maintain long-term cell line stability, 
recombinant protein expression was measured after four day production runs for each 
passage up to 20 passages. In addition, the recombinant protein expression was detected 
in cell lysates by western blot to visualize any changes in protein over several passages. 
Western blots display consistent expression up to passage 20 (Figure 17A). At passage 
25, the recombinant protein seems to be expressed at a slightly lower molecular weight. 
Although the protein appeared to be expressed differently, normal molecular weight 
returned by passage 30, but with lower expression. The protein titer decreased at passage 
25 but was still higher than the titer from passage 1, indicating that the SP2/0 clone is 
stable at least up to 20 passages (Figure 17B).  In addition, the method used to transfect 
SP2/0 cells and isolate high-yielding clones is capable of establishing cell lines with 
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protein stability up to 20 passages.  
A 
 
 
 
Figure 17. Determining SP2/0 clonal cell line stability 
 
Recombinant protein titers were quantified over 30 passages to determine long-term 
recombinant protein production in a stable SP2/0 cell line, clone 2H3. A) Western blot 
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bands display expression of the recombinant lysosomal enzyme (top) along with a 
Ponceau S stain to demonstrate equal loading (bottom). B) Enzyme activity titers after a 4 
day production run for over 30 passages. 
 
3.3 Quality and Functionality of SP2/0 Products 
 
Comparison of ERT Drug Uptake from CHO cells and SP2/0 cells 
SDS-PAGE reveals that the ERT produced in CHO and SP2/0 cells have the same 
molecular weight of 65 kDa (Figure 18). To verify that the recombinant proteins 
produced by SP2/0 cells can be used for research applications, the recombinant proteins 
were tested for function in two cell-based experiments. Purified SP2/0 and CHO 
produced ERT were administered to diseased lysosomal storage disorder fibroblasts at six 
concentrations to generate a dose-response curve. Cellular uptake of the ERT was 
quantified for each ERT dose. The dose response curve was fit to the Michaelis-Menten 
equation on Graphpad Prism 7. Both CHO and SP2/0 cells have similar Kuptake, 4.5 and 
4.6, respectively (Figure 19). Although Kuptake values of SP2/0 and CHO cells are similar, 
the SP2/0-produced ERT had a higher Vmax compared to CHO cells. Overall, this 
experiment demonstrates that cellular uptake of CHO and SP2/0 produced ERTs are 
comparable. 
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Figure 18. Western blot of the CHO and SP2/0 produced ERT 
 
0.1 µg ERT sample produced from CHO (CHO-ERT) and SP2/0 (SP2/0-ERT) cell hosts 
used for protein comparison studies in this experiment were separated by non-reducing 
SDS-PAGE. The gel was then transferred to a nitrocellulose membrane and probed using 
a polyclonal antibody specific to the proprietary ERT. The sizes of the ERTs were 
estimated using the molecular weight markers, labeled in kDa.  
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Figure 19. Comparison of Kuptake for SP2/0 and CHO-produced ERT 
 
Six increasing concentrations of SP2/0-produced ERT (green triangle) and the same ERT 
produced by CHO cells (blue circle) were administered to lysosomal storage disorder 
fibroblasts to establish an ERT dose-response curve. Data points were fit to the 
Michaelis-Menten equation on Graphpad Prism 7.0 to determine Kuptake values. Each data 
point represents the results of two replicates. This experiment was repeated twice. 
Representative results are shown.  
 
The enzymatic activity decay of ERT uptake into lysosomal storage disease 
fibroblasts were measured over a 7 day period. The ERT produced in both CHO and 
SP2/0 cells had half-lives of 36.5 hours and 14.9 hours respectively (Figure 20). When 
the ERT is internalized into the cell, it is processed from its full length form at 65 kDa 
into the 25 kDa form (Figure 21).  Although enzymatic activity decay of the ERT is 
similar from both CHO and SP2/0 expression platforms, the ERT processing is different. 
The ERT produced by CHO cells was mostly processed from the full-length 65 kDa form 
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into the 25 kDa form within 24 hours, with full processing after 48 hours. The ERT 
produced by SP2/0 cells was not fully processed into its 25 kDa form after 168 hours. 
The SP2/0-produced ERT are processed slowly, with a continuous increase in expression 
of the 25 kDa processed form over the 168 hour period. Total protein was stained by 
Ponceau S, and showed a gradual increase in amounts of protein over time, as a result of 
fibroblast cell growth (Supplementary Figure 5).  
 
 
Figure 20. Determination of ERT half-life from CHO and SP2/0 production hosts 
 
Lysosomal storage disorder fibroblasts were dosed with 50 nM ERT produced from CHO 
and SP2/0 expression platforms. After a 4 hour incubation period, the ERT dose was 
removed and replaced with DMEM media supplemented with FBS. At each time point, 
the fibroblasts were washed twice and cell lysates were harvested. Cell lysates were 
assayed using a 6-HMU enzyme activity assay to determine concentration of the 
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internalized ERT. The curve was fit to a one phase exponential decay curve on GraphPad 
Prism 7.0 software to calculate the ERT half-life in hours. Each point and error bar 
represents mean and error of two technical replicates. 
 
Figure 21. Half-life comparison of CHO and SP2/0-produced ERTs 
 
Cell lysates from the half-life uptake experiment were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane. The western blot on the left shows cell lysates 
of diseased fibroblasts dosed with 50 nM ERT produced by CHO cells, while the western 
blot on the right shows cell lysates of diseased fibroblasts treated with 50 nM ERT from 
SP2/0 cells. Time points are measured in hours after the ERT was removed (4 hours after 
incubation in the ERT). As a control, diseased fibroblasts were dosed with a diluent, 
DMEM media, without an ERT. The nitrocellulose membrane was probed with a 
monoclonal antibody enzyme specific to the proprietary ERT. Full length-ERT is 
expressed at 65 kDa (indicated by top arrow), and the ERT processed within the 
lysosome is expressed at 25 kDa (indicated by bottom arrow).   
 
 The internalization of an ERT into the cell is mediated by endocytosis after 
binding to the cation-independent mannose-6-phosphate (CI-M6PR) receptor. To further 
explore characteristics of the ERTs, M6P binding to the CI-M6PR was measured for 
seven concentrations of the CHO and SP2/0-produced ERTs, generating an enzyme 
binding curve (Figure 22). Wells of a 96 well plate were coated with 100 µL of 4 µg/mL 
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CI-M6PRs. The ERTs produced from CHO and SP2/0 cells were bound to the CI-M6PR 
during a two hour incubation period at room temperature. ERT bound to the CI-M6PR 
was detected by measuring enzyme activity of cleaved 4-MU conjugated substrate. 
Binding affinity (KD) to the CI-M6PR was calculated by linear regression to for both 
CHO and SP2/0 produced ERTs (Table 1).  
 
 
Figure 22. ERT binding affinity to CI-M6PR 
0.4 µg of the CI-M6PR was bound to each well of a 96 well plate. CHO and SP2/0-
produced ERT was bound to the CI-M6PR and was measured for fluorescence released 
from cleaved 4-MU conjugated substrate. Each data point represents variability of two 
assays, each with two technical replicates.  
 
 
ERT Host Lineweaver-Burk  Hanes-Woolf  
KD KD 
CHO 12.54 10.23 
SP2/0 10.36 9.21 
 
 
 
  
Table 1. Binding affinity summary of ERT to CI-M6PR 
 
Binding affinities of M6P residues on CHO and SP2/0 ERTs to the CI-M6PR was tested. 
The KD determined for the binding of the M6P residue on CHO or SP2/0-produced ERT 
to the CI-M6PR was calculated by linear regression using Lineweaver-Burk and Hanes-
Woolf. KD values are reported in nM.  
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4.0 DISCUSSION  
 
As research and development groups continue to develop therapeutic proteins, 
there is increasing demand for efficient expression of a variety of recombinant proteins 
including biotherapeutics and protein reagents. Some proteins including lysosomal 
enzymes are especially difficult-to-express, yielding considerably low titers, making the 
cell line development process timely, costly, or unsuitable for manufacture. Instead of 
altering multiple molecular pathways to force expression of a difficult protein, another 
cell line may already possess the cellular machinery required to express the protein of 
interest. With multiple expression platforms available for recombinant protein 
production, difficult-to-express proteins can be produced more efficiently, and cell lines 
can be developed quicker.  
To address the lab’s need for additional mammalian recombinant protein 
expression platforms for production of difficult-to-express proteins, this project explored 
the use of a SP2/0 expression platform for a difficult-to-express lysosomal enzyme. After 
establishing a stable cell line, a bioprocess capable of producing milligram quantities of a 
difficult-to-express recombinant protein was developed. Finally, the same recombinant 
protein expressed in CHO and SP2/0 were compared to determine whether protein 
function was affected by the expression host. This project successfully identified a 
working SP2/0 expression platform capable of producing milligram quantities of a 
research-grade recombinant protein that is difficult-to-express. The fed-batch process 
established may be used as an additional expression system for production of difficult-to-
express recombinant proteins, for research-grade therapeutics or reagents.  
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4.1 Assessment of GS-Based Selection System for the SP2/0 Expression Platform 
 
This project first evaluated the GS-based selection method for isolating high-
yielding SP2/0 clones. One of the main concerns about using the GS-based selection 
method for SP2/0 cells was that non-transfected cells would be able to survive due to the 
low levels of endogenous GS expression. An accepted GS-based selection method for 
cell lines that endogenously express GS requires the supplementation of small amounts of 
MSX to the cell culture to inhibit GS (Birch, Mainwaring, & Racher, 2008). To 
determine whether MSX was required for the selection of transfected SP2/0 cells, the 
SP2/0 cell line was tested for glutamine dependence. When removing glutamine from the 
media, SP2/0 cells were not capable of synthesizing enough glutamine for survival, 
requiring an exogenous source of GS. Thus, the GS-based selection system can 
successfully eliminate non-transfected SP2/0 cells without the use of MSX. Furthermore, 
protein expression levels of the top-yielding clone, 2H3, demonstrated long-term 
maintenance of protein expression (Figure 17). This ensures that the co-expression of GS 
and the recombinant protein is still favored in glutamine-free conditions even with the 
expression of endogenous GS. To this end, the implemented clonal selection strategy of 
combining selection pressure with high resolution imaging can be used to quickly select a 
high-yielding stable SP2/0 clone within 5-6 weeks. To further improve production yields 
and long-term recombinant protein expression from SP2/0 cells, a larger number of 
clones could be screened.  
4.2 Bioprocess Analysis 
 
In a fast-paced industry setting, many high-quality recombinant proteins need to 
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be expressed simultaneously for several different projects at the early research stage. For 
SP2/0 cells to be considered a valuable expression tool for early stage research purposes, 
the SP2/0 generated cell lines need to be able to yield high amounts of protein after a few 
optimizations. This project focused on three bioprocess optimization strategies and one 
selection pressure strategy, each of which could be used to increase protein production 
titers.  
The first bioprocess optimized for the SP2/0 production platform was the cell 
culture media. Cell culture basal media is one of the most critical components of cell 
based expression platforms since it is the central supply of nutrients to the cells, directly 
influencing cell growth and viability. For this reason, culture media is generally one of 
the first few components of the bioprocess that is optimized. In addition to cell health, 
media can also influence glycan distribution on recombinant proteins (Wells & Robinson, 
2016). Today, culture media with different formulations of sugar content, amino acids, 
and serums are commercially available to fit protein production needs for specific cell 
lines (Wells & Robinson, 2016). Selecting the optimal media that supports high cell 
density, with minimal reduction in viability or cellular phenotype is vital to maintaining 
the quality of recombinant proteins. For this project, five commercially available serum-
free media specific for hybridoma or myeloma host cell lines were screened for optimal 
cell health and productivity. As seen in Figure 11, different media formulations can 
greatly influence cell health and productivity. When comparing Media A to Media C, 
basal media was capable of having devastating effects reducing productivity from an 
average titer of 19.6 mg/L to 0.33 mg/L, as a result of a dropping in viability from 96.7% 
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to 3%. Results from this project suggests that Media A boosts productivity and cell 
growth, making it an ideal basal media for both production and culture maintenance 
(Figure 11). When selecting an optimal media, other parameters for example specific 
productivity, the amount of recombinant protein produced per cell, also need to be taken 
into consideration. For example, Media A was able to support rapid cell growth rates and 
cell density up to 9 million cells per mL, compared to Media D, which maintained cell 
density under 1 million cells per mL. Although Media D did not support high cell 
density, it supported higher specific productivity, shifting cellular energy was towards 
recombinant protein production rather than cell division. This allowed the Media D to 
yield an average titer of 15.17 mg/L, comparable to the titers of Media A 19.64 mg/L 
despite large differences in cell density. It should be noted that only five types of 
myeloma/hybridoma media were screened when there are many other commercially 
available media for further optimizations. Perhaps with a larger panel of commercially-
available medium or upon using an optimized in-house media formula for the SP2/0-2H3 
clone, higher productivity and extended viability could be achieved. For optimization at 
the research stage of therapeutic development, the goal is to identify a few types of media 
that can be quickly screened so multiple clones and cell types can be optimized 
simultaneously. After leading therapeutic candidates and their cell lines are identified at 
the research stage, the production process of these therapeutic candidates will be fully 
optimized in later stages of the therapeutic pipeline. Overall, this project demonstrated a 
straightforward and quick method for selecting a high-yielding basal media for a SP2/0 
production cell line at the research stage of therapeutic development. 
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The second bioprocess optimized was incubation temperature, a widely-used 
method to optimize protein production in industrial cell lines. Inducing mild-
hypothermia, or temperature shifting, to a lower incubation temperature is known to 
suppress cell growth, reduce glucose consumption, and extend viability, ultimately 
enhancing protein productivity (Furukawa & Ohsuye, 1998; Kumar et al., 2008; Moore et 
al., 1997). Temperature shifting has mainly been studied in CHO cells, and usually 
supports an increase in productivity. In contrast, the effect of temperature shifting in 
murine myeloma or hybridoma cells can vary depending on the cell line being used and 
the protein expressed (Furukawa & Ohsuye, 1998; Mason, Sweeney, Cain, Stephens, & 
Sharfstein, 2014).  Generally, reports of temperature shifting in murine myeloma or 
hybridoma cell lines decrease productivity or does not affect productivity (Al-Fageeh, 
Marchant, Carden, & Smales, 2006). Unlike general reports, temperature shifting using 
our SP2/0 clone slightly benefits protein production when temperature shifted to 32˚C on 
days 0, 1 or 2 of the protein production process (Figure 12). By temperature shifting early 
in the production run, maximum cell density was not reached until the last day of the 
production run, ultimately extending viability. This was not the case for cell cultures 
shifted after day 3 since cultures reached their maximum cell density before the end of 
the production run. Temperature shifting provided excellent viability throughout the 
production process, which could contribute to maintaining the quality of recombinant 
proteins. Protein production in our proof-of-concept model was slightly improved using 
temperature shifting, but should be optimized per generated SP2/0 cell line as previous 
reports of temperature shifting on myeloma and hybridoma cell lines can have varied 
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results. Furthermore, each clone can have varying responses to temperature shifting 
(Yoon et al., 2004), and temperature shifting may have a different effect depending on 
the recombinant protein being expressed (Mason et al., 2014). Although reports in the 
literature have stated that temperature shifting usually does not increase production in 
murine myeloma cell lines, the results from this project suggests that temperature shifting 
may be beneficial for clones that require higher viability throughout the protein 
production process. 
To further investigate ways to improve the SP2/0 expression platform, a fed-batch 
bioprocess was adapted and tested using a panel of serum-free and commercially 
available nutrient feed. Fed-batch cell culture is commonly used for recombinant protein 
production since it offers a simple method to boost production by replenishing depleted 
nutrients, it is reproducible at a large scale, and it gives experimental control over relative 
nutrient levels (Khattak, Xing, Kenty, Koyrakh, & Li, 2010). For this reason, many 
therapeutics are manufactured using a fed-batch process with both mouse myeloma and 
CHO cell hosts, producing therapeutics including but not limited to Synagis 
(AstraZeneca), Erbitux (Eli Lilly & Company), Humira (AbbVie), Herceptin (Roche), 
and Rituxan (Genentech and Biogen Inc.). Similar to basal media, nutrient feed had 
drastic effect on protein production using the SP2/0 clone, either reducing titers from 
16.9 mg/L to 0.76 mg/L, or doubling production titers (Figure 14). It was observed that 
over-feeding the cells by adding feed on day 0, 3 and 5 did not benefit production (Figure 
13). From these results, we hypothesize that nutrient overfeeding increased the amount of 
accumulated toxic waste metabolites in the culture. Feeding strategy was further 
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investigated by implementing a different feeding strategy, replenishing depleted nutrients 
by adding ten percent feed on days 3 and 5. The second feed strategy had a beneficial 
effect resulting in doubling titers, extending viability and cell growth (Figure 13). These 
results suggest that feeding strategy has a drastic impact on recombinant protein 
production, and that feed strategy should be optimized to maximize protein titers. Similar 
to the media optimizations performed in this project, a larger nutrient feed panel of 
commercially-available feed or an in-house optimized nutrient feed panel could be 
screened for further optimization. This experiment successfully developed a quick and 
practical approach to screening a panel of feed for the identification of two types of 
nutrient feed capable of doubling production titers. Together, nutrient feed and basal 
media optimizations had the most impact on raising production from the SP2/0 clone. 
The SP2/0 cells used in this project expresses low levels of GS, but still require 
glutamine to survive (Figure 5), similar to what is reported in literature reviews (Birch et 
al., 2008). Expression systems which utilize the GS expression system can amplify copy 
number of the gene encoding the recombinant protein by adding MSX, a GS inhibitor, to 
add selection pressure (Nakamura & Omasa, 2015). The GS expression system is an ideal 
selection method for SP2/0 cells since they express low levels of endogenous functional 
GS compared to CHO cells.  
The MSX selection pressured SP2/0 clone successfully increased recombinant 
protein activity using a single round of selection pressure without cloning for all four 
concentrations of MSX within a three week time frame (Figure 16). Within three weeks 
of 50 µM MSX selection pressure, titers were able to double. 50 µM MSX seems to be a 
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reasonable selection pressure concentration for SP2/0 cells according to our results and 
previous reports of MSX concentrations for cell lines of varying endogenous GS levels. 
For example, NS0 expression systems, which are GS deficient, usually maximizes 
recombinant protein expression or gene copy number at MSX concentrations of 10-100 
µM. Due to high levels of functional endogenous GS in CHO cells, GS-CHO expression 
systems usually maximize gene amplification at 250- 500 µM MSX (Barnes, Bentley, & 
Dickson, 2000). Although there are limited literature reports reporting the range of MSX 
concentrations in SP2/0 cells, the optimal MSX selection pressure concentration is likely 
to be between 10-100 µM (GS-NS0 range with little to no endogenous GS) and 250-500 
µM (GS-CHO range with higher endogenous GS). By using 50 µM MSX, a slightly 
lower MSX concentration predicted for SP2/0 cells, unfavorable effects of MSX 
including cellular toxicity and cell line instability are minimized. However, it would be 
valuable to explore the effects of higher MSX concentrations on SP2/0 cells. A limitation 
to the current gene amplification process by MSX is that adding the best performing 
nutrient feed with the 50 uM MSX clone did not have a synergistic effect with nutrient 
feed (Supplementary Figure 4). Currently, results from basal media, nutrient feed, and 
MSX selection experiments suggest that SP2/0 cells have great potential for titer 
improvements after several process optimizations.  
4.3 Comparative Analysis of Therapeutic Protein Quality from CHO and SP2/0 
Cell Hosts 
 
To consider SP2/0 cell as production hosts for recombinant therapeutics, the 
SP2/0-produced protein therapeutic product needed to demonstrate comparable quality to 
the same therapeutic known to be research-grade quality. The ERT expressed in CHO 
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cells was previously tested and is known to be our research-grade ERT for in vitro 
studies. One criteria for recombinant protein production is that protein expression in 
SP2/0 cells should not interfere with protein functionality. To be considered research-
grade, the ERT needs to meet several criteria including similar molecular weight, uptake 
into a diseased cell, half-life and processing within a diseased cell. The first round of 
comparative studies verified that the ERT is expressed at the same molecular weight, 
indicating that the SP2/0 cells are not likely to add or delete any part of the protein 
(Figure 18). Furthermore, this suggests that any differences identified between SP2/0 and 
CHO produced ERTs are likely due to host cell post-translational modifications. ERT 
therapeutic uptake into diseased cells in vitro is similar, regardless of the production host. 
Interestingly, the therapeutic produced in SP2/0 host cells had a higher VMax which 
suggests that a higher amount of the SP2/0-produced ERT was able to enter the cells 
compared to CHO. Alternatively, a higher VMax could be due to assay variability if more 
cells were harvested from the fibroblasts treated with SP2/0-produced ERT.  
In addition to similar uptake values, SP2/0 and CHO expression platforms 
produced ERTs with similar binding affinities to the CI-M6PR (Figure 22). This feature 
is critical to ERT drug efficiency, since the CI-M6PR is the receptor responsible for the 
binding and internalization of M6P-tagged lysosomal enzymes from the extracellular 
space into the cell and ultimately to the lysosome (Saftig, 2006). Similar KD values 
suggest that binding to the CI-M6PR is not affected and it is unlikely that there are 
variations in M6P post-translational modifications between the two cell lines. These 
results seem to correlate to the similar uptake values, suggesting that similar ERT binding 
  
72 
 
affinities to the CI-M6PR receptor would facilitate similar uptake into the cell.  
Although cellular uptake is similar, differences in ERT half-life were identified, 
showing over two times faster ERT degradation in the SP2/0 produced ERT compared to 
the CHO produced ERT (Figure 21). Interestingly, fibroblast lysates from an uptake half-
life experiment showed differences in intracellular processing of the ERT. Normally, the 
ERT is known to be processed from its full-length 65 kDa precursor form, into the active 
25 kDa form inside the lysosome. The ERT from the CHO cells follows these normal 
processing steps. In the SP2/0-produced ERT the full-length ERT is maintained in the 
full-length form and is slowly processed into the 25 kDa form, showing an increase in the 
25 kDa expression until the 168 hour time point. These results are inconsistent with the 
half-life generated by the enzyme activity assay, showing decreasing recombinant 
enzyme expression over time. We propose two hypotheses explaining the internalized 
SP2/0-produced ERT western blot results. First, the ERT from the SP2/0 host may not be 
internalized into the cell and instead, could be immobilized at the cell surface. One reason 
internalization of the ERT may be affected is due to the semi-pure state of the SP2/0-
produced ERT, allowing some molecules to interfere with pathways involving the M6P-
mediated internalization. The uptake and processing of the SP2/0-produced ERT could be 
different after complete purification. Second, the ERT may be internalized into the cell 
but is not being processed into its active form due to various interactions with other 
molecules within the cell. Differences in intracellular molecule interactions could be due 
to variation in SP2/0 post-translational modifications or protein structure. These 
differences visualized by the western blot need to be further investigated, first by 
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understanding where the SP2/0-produced ERT localizes into the diseased cells. In 
addition, comparing protein structure and glycan distribution of the CHO and SP2/0 
ERTs could provide better understanding about structural differences which could 
interfere with the enzyme processing.  Understanding these intracellular processes may 
hold great potential in improving therapeutic efficacy, providing hints to manipulations in 
the ERT that could extend the half-life.   
   
5.0 CONCLUSION 
 
To address our lab’s need for alternative production platforms for efficient 
expression of a diverse set of proteins, this project established a working SP2/0 
expression platform capable of producing milligram quantities of a difficult-to-express 
recombinant protein. The cloning process was quick, demonstrating an effective way of 
establishing a high-yielding SP2/0 clone within 5-6 weeks. Furthermore, this project 
proposes several optimization strategies for doubling recombinant protein titers in SP2/0 
cell lines. Importantly, the therapeutic efficacy of lysosomal enzyme proteins is 
comparable in both SP2/0 and CHO cells, showing similar cellular uptake and binding 
affinity to the CI-M6PR. However, there are some differences in intracellular processing 
of the ERT produced in SP2/0 cells, suggesting some interference with either the 
internalization of the ERT or the processing of the ERT within the cell. This phenomena 
could be explored more thoroughly, as extending the half-life could have great potential 
on improving therapeutic efficacy. From this project, we propose that having SP2/0 cells 
as an additional mammalian expression platform for recombinant protein production is 
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valuable since it offers new benefits to our existing expression system including 
expression of a difficult-to-express protein, quick process optimization to double titers, 
long-term cell line stability, and demonstrates similar cellular ERT uptake in diseased 
cells. 
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6.0 SUPPLEMENTARY FIGURES 
 
 
Supplementary Figure 1. Post-transfection media optimization 
 
24 hours post-transfection, transfected cells were split into three different types of 
glutamine-free media: SP2/0-BMN (A), SP2/0-BMN-2 (B), and SP2/0-BMN-3 (C). 
Bright field images were taken 24 hours after incubating in the media. Healthy cells post-
transfection are visualized in small cell colonies indicated by the black arrows in figure 
B. Scale bars represent 400 µm.  
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Supplementary Figure 2. Media optimization during clone expansion 
 
A cell population of a SP2/0-GS-ERT clone was split into two wells of a 24 well plate, 
each with different media either SP2/0-BMN-2 (A) or SP2/0-BMN (B). Bright field 
images were taken 24 hours after media was administered to the cells. During clonal 
expansion, cells in SP2/0-BMN-2 media adapted to adherent culture conditions, seen by 
their elongated morphology (A). SP2/0-BMN media kept the cells in a suspension-
adapted culture, seen by their round shape. Scale bars represent 400 µm.  
 
 
Supplementary Figure 3. SP2/0 media optimization summary 
 
Summary of optimal media for growth of suspension-adapted SP2/0 clones during early 
phases of cell line development.  
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Supplementary Figure 4. Combined effects of nutrient feed and MSX pressured 
cells on protein expression and cell health 
 
SP2/0 clone 2H3 was pressured in methionine sulphoximine (MSX) concentrations at 
either 5 µM, 10 µM, 20 µM, 50 µM, or no MSX for three weeks. On days 3 and 5, 10% 
volume feed was added to some of the flasks. Shake flasks were seeded at 0.5 million 
cells per ml and sampled daily to monitor cell health including viability and growth (A, 
B, D, and E). For days 1-7 of the production run, protein production titers were measured 
by an enzyme activity assay (C and F).  
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Supplementary Figure 5. Ponceau S total protein stain of cell lysates dosed with 
CHO and SP2/0-produced ERT 
 
Cell lysates from the half-life uptake experiment were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane. The membrane on the left shows cell lysates of 
diseased fibroblasts dosed with 50 nM ERT produced by CHO cells, while the membrane 
on the right shows cell lysates of diseased fibroblasts treated with 50 nM ERT from 
SP2/0 cells. Time points are measured in hours after the ERT was removed (4 hours after 
incubation in the ERT). As a control, diseased fibroblasts were dosed with a diluent, 
DMEM media, without an ERT. Protein was stained red with Ponceau S stain.  
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